Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, I’m not looking at Thinkorswim, but it’s there I presume. No, I see the volume on the basic TDAmeritrade webite’s NWBO Stock Profile Page after I tap “NWBO” on the Positions Page.
My TDAmeritrade is showing 419,120 (Heavy Day)
Many informative and encouraging posts lately.
This tactic has Cofer Black written all over it ;)
Some may be willing to sacrifice style as long as the content is accurate. I almost fell asleep reading it, but it was helpful. :)
Actually, twenty cents to one dollar would be a 400% increase (.8 / .2 = 4) ;)
I’ll give you 16c on Monday if you give me $25 in 2021.
Tough decision. Of course, this short term spike would still be considered a dip three years from now if all goes well for NWBO. But I understand that the trading game is played differently.
I agree. I read the section of the text several times, and I don’t see any evidence of Class I exempt status in the U.S. I interpret the 10-k to state that the AC5 Topical Gel is Class II in the EU and US and that the other AC5 products’ classification has not been determined yet in either location. I’m referring to the following paragraph from the 10-k:
“Medical devices in the EU and the U.S. are classified along a spectrum. Class III status, which is the higher-level classification for devices compared to Classes II and I, involves additional procedures and regulatory scrutiny of the product candidate to obtain approvals. AC5 could be regulated as either a Class III or a Class II medical device in these jurisdictions, depending upon the application, subject to the process for obtaining a CE mark in the EU and the premarketing authorization process in the U.S. It has been determined that our AC5™ Topical Gel used for external wounds will be a Class II medical device.”
So, if the AC5 Topical Gel is approved and begins commercialization before Q4 2018, when the cash on hand will be depleted requiring financing/dilution, then ARCH will be in great shape going forward. This is just my opinion.
The MM do their thing, and I do mine, which is to buy and average down during the dips. I’m new to ARCH and initially bought in the .70s.
FYI, I have a margin approved account with TDAmeritrade, and so Level 2 bid/ask data is free with their Think or Swim app.
On ARTH Level 2 bid and ask, I see CSTI, NITE, and CDEL, market makers that have manipulated NWBO’s share price to death this past year. This is not a good sign in the short term, but good news will win the day eventually IMO.
I think it will be just the same as before, OS data needs to mature to increase the likelihood of L being approved so that patients get access and your investment doesn’t get wiped out.
That’s an often lost but important fact which supports a long strategy.
That’s my guess, too. I remember reading on this board about the recent activities in Canada, but I won’t be disappointed if I’m wrong.
You are as eloquent as you are brilliant.
Iron some of your dresses. You’ll feel better.
We may never know the reason(s), but I trust that the option to lease didn’t just recently occur to LP and company.
At the risk of stating the obvious, the reason could be simple supply and demand economics. Landlords often can’t find tenants willing to lease properties at a particular asking price.
I still see nothing but unicorns and rainbows.
A physician on NWBO’s board alerted me to ARTH awhile back, and I finally bought a chunk on Friday. Timing wise, I need two more end-of-month paydays to meet my share count goal, but if I miss a major uptick, so be it. I’ll still buy ARTH in the low single digits. Although I don’t think it will happen, I’m hedging against being wiped out at NWBO. Biotech is not for the faint-hearted.
Agreed. Trust that the DCVax-L trial will be completed when it’s supposed to be completed. Worrying about the outcome won’t change anything. I pray to God he speeds it up for the sake of the patients and their loved ones.
Yes, but companies can be undervalued, or overvalued, due to forces outside pure investment theory.
The latter wouldn't be nearly as easy as the former.
Assuming it's true, NWBO cannot announce the terms of a financing that hasn't been completed. That would be foolish. If the deal has been leaked beforehand, management cannot be held responsible. The leak would be completely out of their control.
Smith states that mOS is an independent co-primary endpoint. Was this changed? I thought that mOS was a secondary endpoint. In case mPFS is confounded due to crossover, it bodes well for longs that mOS is considered as an indpendent co-primary, does it not? Thank you.
I seriously doubt that NWBO is using SOS as a mouthpiece to communicate corporate strategy. What would be the point? NWBO gains no advantage by doing so IMO. However, there are many reasons why it would be bad idea.
Customize your Positions page with volume and you'll see the current daily figure.
No argument there.
Someone posted awhile back that NWBO's legal insurance covers supposed settlements like this.
Same. As many on this MB know, this story is all too common. Regards.
I tell people that my dear mother died of lung cancer, but in fact, lung cancer was only primary. It had metastasized to her brain in the end.
Good point.
If DCVax-L is approved, could a GBM patient decline chemo/radiation and only opt for the vaccine?
I think U.S. federal law dictates that FDA clinical review trials be designed with minimum statistical thresholds in order for a drug or device to be approved. But I agree with your post. You would think equaling standard of care with a product that has DCVax's safety record would be sufficient for approval.
Your comment is accurate and fair. Let's call it the whale omelette factor.
I suspect few people even know the half of it.
I see the same stuck volume for NWBO on my TD Ameritrade account, but my customized position page which includes volume accurately displays current daily volume for NWBO. Hope this helps.
I am willing to wait because I trust that NWBO, the DMC, and the FDA will come through on their parts. Waiting has a purpose, and it's to ensure that all the stakeholders, especially the patients, don't miss out on this imminent paradigm shift in the way cancers are treated.